Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17120815 | 0.86 | LMNA (0.56) | KDM4ELMNA | |
| SCHEMBL17119505 | 0.80 | KDM4E (0.38) | KDM4ELMNAAOC3 | |
| SCHEMBL16675429 | 0.71 | LMNA (0.59) | KDM4ELMNA | |
| SCHEMBL20804156 | 0.71 | LMNA (0.42) | KDM4ELMNAAOC3 | |
| SCHEMBL9970098 | 0.70 | LMNA (0.71) | KDM4ELMNAAOC3 | |
| SCHEMBL9970107 | 0.70 | AOC3 (0.39) | KDM4ELMNAAOC3 | |
| SCHEMBL9970110 | 0.69 | LMNA (0.38) | KDM4ELMNAAOC3 | |
| SCHEMBL14646864 | 0.67 | LMNA (0.56) | KDM4ELMNA | |
| SCHEMBL14646865 | 0.66 | LMNA (0.64) | KDM4ELMNAAOC3 | |
| SCHEMBL9970109 | 0.65 | LMNA (0.44) | KDM4ELMNAAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150265584-A1 | LEVUGLANDIN ADDUCTS HISTONE H4 IN A CYCLOOXYGENASE-2-DEPENDENT MANNER, ALTERING ITS INTERACTION WITH DNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265584-A1 | LEVUGLANDIN ADDUCTS HISTONE H4 IN A CYCLOOXYGENASE-2-DEPENDENT MANNER, ALTERING ITS INTERACTION WITH DNA | H1-2, H1-4, H1-3 | KDM4E 330/4885LMNA 174/4885AOC3 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.